StemCell Therapy

– UDENYCA® autoinjector approved and ready for May 2023 launch –– CIMERLI® product-specific Q-code now facilitating electronic reimbursement following April 1 activation –– FDA inspection of toripalimab manufacturing site scheduled for May 2023 –– Toripalimab launch anticipated in Q3 2023, if approved –– YUSIMRY™ ready for planned July 2023 launch –– FDA review of UDENYCA® OBI BLA supplement progressing; launch anticipated in 2023, if approved –– Net product revenue of $32.4 million in the first quarter 2023 –– Conference call today at 5:00 p.m. Eastern Time –

Go here to read the rest:
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights

CAMBRIDGE, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2023 financial results will be released on Monday, May 15, 2023 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Originally posted here:
Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET

SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) --  NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that results of a Phase 2 investigator-sponsored trial of aldafermin for the treatment of patients with idiopathic BAM with IBS-D were presented at Digestive Disease Week 2023.

Original post:
NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant...

Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer

The rest is here:
ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

Pivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma accelerating globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 anticipated in 2Q 2023

Read the original here:
Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

EMERYVILLE, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced today it will participate in the following upcoming investor conferences:

Excerpt from:
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences

VANCOUVER, British Columbia, May 08, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2023 and provided a summary of recent business highlights.

Go here to see the original:
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results

IND cleared and enrolling patients in SC291 Phase 1 clinical trial in B-cell malignancies with initial data expected later this year

Continue reading here:
Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates

Global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; execution of global geographic footprint

See the original post here:
Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

SALT LAKE CITY, May 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has achieved the Great Place to Work® certification for 2023.

Continued here:
Myriad Genetics Earns 2023 Great Place to Work Certification™

SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, May 15, 2023 at 2:00 p.m. Pacific Time to discuss its financial and operating results for the first quarter 2023 as well as provide a corporate update, which may include an update concerning the results of the company’s special meeting of stockholders scheduled to be held on May 15, 2023 at 10:00 a.m. Pacific Time as well as the proposals to be considered and acted upon at the meeting. The company’s first quarter 2023 financial results news release is expected to be available after 1:00 p.m. Pacific Time on May 15, 2023, and on its website.

View original post here:
Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update

Q1 2023 revenue $21.4 million, 27% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million

Read more here:
Akoya Reports Record Revenue in the First Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance

SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will provide a corporate update and participate in one-on-one investor meetings at the JMP Securities Life Sciences Conference, to be held in New York, NY, from May 15-16, 2023.

Go here to read the rest:
BioAtla to Participate in the JMP Securities Life Sciences Conference

Reiterates 2023 Financial Guidance Reiterates 2023 Financial Guidance

Here is the original post:
Certara Reports First Quarter 2023 Financial Results

MALVERN, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 27,250 shares of its common stock to seventeen newly-hired employees, with a grant date of May 5, 2023 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.

Read more from the original source:
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Hypoimmune-modified allogeneic iPSCs evade immune response and rejection without immunosuppression in non-human primate model

Go here to see the original:
Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection...

First patient dosed in Quoin’s single arm, open label clinical trial in Netherton Syndrome patients currently receiving off-label systemic therapy

Link:
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results

MALVERN, Pa., April 14, 2023 (GLOBE NEWSWIRE) --  Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced positive preliminary data among retinitis pigmentosa (RP) participants treated in the first two cohorts of the Phase 1/2 trial to assess the safety and efficacy of OCU400 for RP associated with NR2E3 and Rhodopsin (RHO) mutations and Leber Congenital Amaurosis (LCA) with mutation(s) in the CEP290 gene. These preliminary results provide support that OCU400, Ocugen’s first-in-class therapeutic approach utilizing a proprietary modifier gene therapy platform, has the potential to be a gene-agnostic therapeutic for RP and LCA patients with inherited retinal degeneration.

Follow this link:
Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for...

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for April 2023. CENTOGENE representatives will be attending events in Spain, the U.S., and Germany and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities. The Company invites attendees to schedule one-on-one meetings in advance.

Continue reading here:
CENTOGENE to Participate in Upcoming Conferences in April

SEATTLE and VANCOUVER, British Columbia, April 14, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of Achieve, will present at the Life Science Innovation Northwest (LSINW) 2023 Conference being held at the Seattle Convention Center April 25-26, 2023.

Read the original post:
Achieve Life Sciences to Present at Life Science Innovation Northwest 2023 Conference